1. Risk Score Based on Two microRNAs as a Prognostic Marker of Hepatocellular Carcinoma and the Corresponding Competitive Endogenous RNA Network
    Xiao-Chun Huang et al, 2021, International Journal of General Medicine CrossRef
  2. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
    Xinyao Hu et al, 2021, Frontiers in Oncology CrossRef
  3. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
    Shengwei Tao et al, 2023, Frontiers in Immunology CrossRef
  4. The current status and future of PD-L1 in liver cancer
    Liyuan Hao et al, 2023, Frontiers in Immunology CrossRef
  5. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment
    Chen Xue et al, 2022, Frontiers in Immunology CrossRef
  6. Cancer‐derived non‐coding RNAs endow tumor microenvironment with immunosuppressive properties
    Tong Hu et al, 2024, WIREs RNA CrossRef
  7. Anti-angiogenic Drug Resistance: Roles and Targeting of Non-coding RNAs (microRNAs and long non-coding RNAs)
    Masoumeh Eliyasi Dashtaki et al, 2023, Current Molecular Pharmacology CrossRef
  8. Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis
    Kadeerjiang Musha et al, 2022, Disease Markers CrossRef
  9. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
    Xinchen Tian et al, 2022, Frontiers in Pharmacology CrossRef
  10. CircFMN2 Boosts Sorafenib Resistance in Hepatocellular Carcinoma Cells via Upregulating CNBP by Restraining Ubiquitination
    Chen Fan et al, 2022, Journal of Oncology CrossRef
  11. Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma
    Mohamed H. Yousef et al, 2020, BioMed Research International CrossRef
  12. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
    Xuehao Zhou et al, 2022, Frontiers in Oncology CrossRef